Detalles de la búsqueda
1.
Factors Associated with Health Care Providers' Preference for Forgoing an Oral Lead-In Phase When Initiating Long-Acting Injectable Cabotegravir and Rilpivirine in the SOLAR Clinical Trial.
AIDS Patient Care STDS
; 37(1): 53-59, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36626155
2.
Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial.
Lancet HIV
; 10(9): e566-e577, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37567205
3.
Safety and efficacy of a 36-week induction regimen of abacavir/lamivudine and ritonavir-boosted atazanavir in HIV-infected patients.
HIV Clin Trials
; 11(2): 69-79, 2010.
Artículo
en Inglés
| MEDLINE | ID: mdl-20542844
4.
High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients.
Clin Infect Dis
; 46(7): 1111-8, 2008 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-18444831
5.
Short-term safety and tolerability of a once-daily fixed-dose abacavir-lamivudine combination versus twice-daily dosing of abacavir and lamivudine as separate components: findings from the ALOHA study.
Pharmacotherapy
; 28(3): 314-22, 2008 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-18294111
6.
The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial.
Lancet
; 368(9534): 476-82, 2006 Aug 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-16890834
7.
Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.
AIDS
; 23(12): 1547-56, 2009 Jul 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-19542866
8.
First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America.
AIDS
; 22(13): 1673-5, 2008 Aug 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-18670229
Resultados
1 -
8
de 8
1
Próxima >
>>